Your Messages Inbox
Your Article Summary
See Latest ArticlesMercks ISENTRESS Tablets Studied in Comparison to Efavirenz in Combination Therapy Through 96 Weeks in HIV-1 Treatment-Naïve Patients
Merck & Co., 09/14/09
ISENTRESS, an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels and at improving CD4 cell counts in previously untreated HIV–1–infected patients through 96 weeks in a Phase III study called STARTMRK. In STARTMRK, ISENTRESS patients received either ISENTRESS or efavirenz in combination therapy. The data was presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy in San Francisco, CA.
Today in Conferences/Meetings...keeping you current
Receive free subspecialty "5-minute updates" via email
ImmunoGen, Inc. Announces Conference Call to Discuss Clinical Data Reported at Recent Medical Meetings
ImmunoGen, Inc., 12/04/09
Allos Therapeutics to Launch Global Registry for Patients with Peripheral T-Cell Lymphoma at the American Society of Hematology Annual Meeting
Allos Therapeutics, 12/04/09
Cytokinetics Announces Non-Clinical Data Relating to GSK-923295 to be Presented at the 32nd Annual San Antonio Breast Cancer Symposium
Cytokinetics, 12/04/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
Amgen, 12/04/09
Bayer Team wins the “Deutscher Zukunftspreis” awarded by the German President
BayNews International, 12/03/09
GSK Update: GSKs Arepanrix H1N1 pandemic vaccine prequalified by the World Health Organization
GlaxoSmithKline, 12/02/09
Article Search
Sponsor